GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Filament Health Corp (NEOE:FH) » Definitions » LT-Debt-to-Total-Asset

Filament Health (NEOE:FH) LT-Debt-to-Total-Asset : 0.03 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Filament Health LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Filament Health's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.03.

Filament Health's long-term debt to total assets ratio declined from Sep. 2023 (0.22) to Sep. 2024 (0.03). It may suggest that Filament Health is progressively becoming less dependent on debt to grow their business.


Filament Health LT-Debt-to-Total-Asset Historical Data

The historical data trend for Filament Health's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Filament Health LT-Debt-to-Total-Asset Chart

Filament Health Annual Data
Trend Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
- 0.03 0.24 0.23

Filament Health Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.23 0.30 0.04 0.03

Filament Health LT-Debt-to-Total-Asset Calculation

Filament Health's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=1.297/5.576
=0.23

Filament Health's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=0.13/3.896
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Filament Health  (NEOE:FH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Filament Health LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Filament Health's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Filament Health Business Description

Traded in Other Exchanges
Address
4475 Wayburne Drive, Unit 210, Burnaby, BC, CAN, V5G 4X4
Filament Health Corp is a natural psychedelic drug development company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. The group engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada psilocybin Dealer's License.
Executives
Benjamin Lightburn Director, Senior Officer
Thomas Kineshanko 10% Security Holder
Warren Duncan Senior Officer

Filament Health Headlines

No Headlines